J B Chemicals & Pharmaceuticals Ltd
Healthcare | Mid Cap
J B Chemicals & Pharmaceuticals Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a very strong, low-debt financial structure. The company excels at generating profits from its sales and provides excellent returns to its shareholders. Its growth in revenue and earnings is remarkable, indicating a strong market position. The company is highly solvent, meaning it has a very low risk associated with debt. The primary area of weakness is in operational efficiency, where the use of assets to generate sales is less effective. While its ability to meet short-term obligations is generally good, its immediate cash reserves are more limited. The future outlook is positive, driven by strong growth and profitability, though its operational efficiency lags behind its otherwise stellar financial performance.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio8.40
- Profitability Ratio10.00
- Efficiency Ratio4.00
- Coverage Ratio9.20
- Solvency Ratio10.00
- Liquidity Ratio7.44
- Peer Assessment
- Management AssessmentStrong
- Risk AssessmentStrong
- 1 HourBearish
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekBullish
- 1 MonthBullish
J B Chemicals & Pharmaceuticals Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a very strong, low-debt financial structure. The company excels at generating profits from its sales and provides excellent returns to its shareholders. Its growth in revenue and earnings is remarkable, indicating a strong market position. The company is highly solvent, meaning it has a very low risk associated with debt. The primary area of weakness is in operational efficiency, where the use of assets to generate sales is less effective. While its ability to meet short-term obligations is generally good, its immediate cash reserves are more limited. The future outlook is positive, driven by strong growth and profitability, though its operational efficiency lags behind its otherwise stellar financial performance.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
52.25
Industry Median
28.62
Mid Cap Median
36.34
P/E RATIO
49.64
P/B RATIO
8.47
Industry Median
3.17
Mid Cap Median
7.64
P/S RATIO
8.51
Industry Median
3.42
Mid Cap Median
6.30
Others
PEG RATIO
3.91
EV/EBITDA RATIO
30.85
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2193.5 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤21st Jan 26
Q3 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
The company is experiencing an exceptional phase of growth. It has achieved outstanding increases in its revenue, profits, and earnings for shareholders. This high-growth trend is visible across all key financial areas, from top-line sales to bottom-line net income. The company is also successfully expanding its asset base to support this rapid expansion. This comprehensive and robust growth signals strong market demand for its products and services and effective execution of its business strategy, positioning it well for the future.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 18.65 | 29.91 | 10.64 | 12.46 | 5.87 |
| Operating Profit Growth Rate | -3.04 | 28.18 | 28.88 | 15.05 | 7.27 |
| Earnings Per Share (EPS) Growth | -13.98 | 6.22 | 34.48 | 18.98 | 4.3 |
| Asset Growth Rate | 16.58 | 36.37 | 12.43 | 6.95 | 16.51 |
| Net Income Growth Rate | -14.03 | 6.22 | 34.88 | 19.35 | 7.42 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company exhibits a very strong financial profile from a shareholder's perspective. It consistently delivers excellent earnings, both on an adjusted and cash basis, and shows impressive growth in its intrinsic value per share. Dividend payments are also robust, reflecting a commitment to shareholder returns. A notable aspect is the very high level of capital expenditure. This significant investment in new assets, while a large use of cash, signals a strong focus on future growth and expansion, even though it represents a substantial current financial outlay.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 23.93 | 27.13 | 33.81 | 40 | 45.56 |
| Cash Earnings Per Share (Cash EPS) | 30.6 | 34.93 | 43.19 | 51.94 | 55.69 |
| Book Value Per Share | 142.27 | 165.33 | 182.75 | 214.62 | 259.94 |
| Dividend Per Share (DPS) | 8.23 | 9 | 12.11 | 15.68 | 9.28 |
| Capital Expenditures (CapEx) | 699 | 764 | 260 | 119 | 81 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability is outstanding across all measures. It demonstrates an exceptional ability to convert revenue into profit, from the initial sale down to the final net income. The returns it achieves on the capital invested by shareholders and lenders, as well as on its total assets, are excellent. This top-tier performance indicates a highly efficient business model, strong pricing power, and effective cost controls, positioning it as a leader in profitability within its industry.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.39 | 18.48 | 21.79 | 21.98 | 22.3 |
| Return on Capital Employed (ROCE) | 23 | 22 | 25 | 26 | 26 |
| Return on Equity (ROE) | 18.09 | 16.53 | 18.91 | 19.22 | 17.05 |
| Return on Assets (ROA) | 20.88 | 19.62 | 22.49 | 24.2 | 22.28 |
| Operating Margin | 22.4 | 22.1 | 25.75 | 26.34 | 26.69 |
| Net Margin | 15.92 | 13.02 | 15.87 | 16.85 | 17.09 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company shows significant weakness in its operational efficiency. It appears to be underutilizing its assets, both fixed and total, to generate sales. This suggests that the revenue generated from its capital base is not as high as it could be. Furthermore, the time it takes to sell inventory and collect payments from customers is on the slower side. This combination points to inefficiencies in managing the company's working capital and overall asset base, which could hinder its performance compared to more efficient competitors.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.9 | 1.66 | 1.74 | 1.99 | 2.19 |
| Inventory Turnover Ratio | 5.16 | 6.11 | 5.84 | 5.92 | 5.32 |
| Receivables Turnover Ratio | 5.13 | 5.56 | 5.52 | 5.22 | 5.2 |
| Days Sales in Inventory Ratio | 70.74 | 59.74 | 62.5 | 61.66 | 68.61 |
| Receivable Days | 71.15 | 65.65 | 66.12 | 69.92 | 70.19 |
| Capital Turnover Ratio | 1.12 | 1.09 | 1.17 | 1.14 | 1 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company has a very strong capacity to meet its financial obligations. Its earnings are exceptionally high compared to its interest expenses, indicating an extremely low risk of being unable to service its debt. Additionally, profits provide a good and secure cushion for paying dividends to shareholders. This demonstrates a robust financial position, ensuring that both lenders and investors are well-protected by the company's substantial earnings power, which enhances its reputation for financial reliability.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 102 | 16.42 | 18.09 | 74.92 | 159.67 |
| Equity Dividend Coverage Ratio | 3.03 | 2.94 | 2.94 | 2.7 | 4.76 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's long-term financial stability is exceptionally strong. It operates with a very minimal amount of debt, financing its operations and assets almost entirely through equity. This conservative financial structure makes the company highly resilient to economic downturns and interest rate increases. It carries a very low risk of default, providing a high degree of security for its investors and creditors. The financial foundation is robust and built on a solid base of shareholder equity rather than borrowed funds.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.01 | 0.14 | 0.01 | 0 | 0 |
| Debt to Equity Ratio | 0.01 | 0.16 | 0.01 | 0 | 0 |
| Equity Ratio | 0.99 | 0.86 | 0.99 | 1 | 1 |
| Debt To Asset Ratio | 0.01 | 0.11 | 0.01 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company shows a good capacity to meet its short-term financial obligations. Its assets that can be quickly converted to cash are sufficient to cover its immediate liabilities. This suggests a healthy position in managing day-to-day finances. However, the amount of ready cash on hand is relatively modest compared to its short-term debts, indicating a reliance on converting inventory and receivables into cash to pay its bills. Cash flow from its main business operations provides an adequate but not exceptional buffer.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 2.95 | 2.1 | 1.49 | 2.31 | 2.78 |
| Quick Ratio | 2.01 | 1.45 | 1 | 1.66 | 1.93 |
| Cash Ratio | 0.13 | 0.12 | 0.09 | 0.16 | 0.18 |
| Operating Cash Flow Ratio | 0.39 | 0.95 | 0.78 | 1.1 | 0.87 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Granules India Ltd | 7.73 | 32.77 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Alembic Pharmaceuticals Ltd | 7.54 | 22.23 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 8 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 9 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 32.39 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 13 | Jubilant Pharmova Ltd | 5.71 | 38.62 | Neutral | 1260.00 | 1.25 | 398.00 |
| 14 | Natco Pharma Ltd | 5.69 | 11.22 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 15 | Wockhardt Ltd | 5.07 | 153.40 | Neutral | 652.00 | 19.51 | 199.00 |
| 16 | Pfizer Ltd | 3.45 | 45.22 | Neutral | -82.00 | 157.92 | 300.00 |
Management effectiveness is assessed as strong. This is supported by excellent financial performance, including robust multi-year profit growth and improving margins. The company demonstrates outstanding capital efficiency with high and improving ROCE and ROE, coupled with efficient working capital management shown by a decreasing cash conversion cycle. Financial health is prudent, characterized by low debt levels, a very strong interest coverage ratio, and a consistent history of sharing profits through dividends. The ownership structure reflects confidence, with high, stable promoter holding and increasing investment from FIIs. A recent slowdown in quarterly growth is noted but is outweighed by the strength of long-term and annual metrics across all other categories.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Strong Profit Growth (3-Year CAGR) | 22% | very strong |
| Excellent Capital Efficiency (ROCE) | 26.8% | excellent | |
| Improving Working Capital (CCC) | 117 Days | improving | |
| Prudent Debt Management (D/E Ratio) | 0.13 | strong | |
| High Interest Coverage Ratio | 20.4x | outstanding | |
| Increasing FII Holding | 11.06% | improving | |
| CONS | Recent Quarterly Sales Growth (YoY) | -4.77% | declining |
| Recent Quarterly Profit Growth (YoY) | -17% | declining |
Financial Performance & Growth
The company has demonstrated strong growth over the medium to long term. Compounded profit growth stands at an impressive 22% over three years, and annual profit growth for FY2024 was a robust 33%. Profitability has also shown a positive trend, with the annual Operating Profit Margin (OPM) improving from 22% in FY2023 to 26% in FY2024. Similarly, Net Profit Margin increased from 13.0% to 15.9% in the same period, indicating enhanced efficiency and profitability. However, a point of concern is the recent performance. The Trailing Twelve Months (TTM) profit growth has decelerated to 14%, and the most recent quarter reported a year-over-year sales decline of -4.77% and a profit decline of -17%. This recent slowdown contrasts with the otherwise strong historical growth trajectory.
| Metric | 10 Years | 5 Years | 3 Years | TTM |
|---|---|---|---|---|
| Compounded Sales Growth | 13% | 15% | 10% | 6% |
| Compounded Profit Growth | 18% | 13% | 22% | 14% |
Capital Efficiency & Returns
Management has demonstrated excellent capability in generating returns from its capital base. The current Return on Capital Employed (ROCE) is a very strong 26.8%, and the Return on Equity (ROE) is 21.9%. These figures are superior to the company's historical averages, indicating improving efficiency. The annual ROCE has shown an upward trend over the last few years. Furthermore, working capital management appears highly efficient. The Cash Conversion Cycle (CCC) has steadily improved, decreasing from 164 days in FY2022 to 117 days in FY2024. This reduction signifies that management is converting its working capital into cash more quickly, which frees up capital and improves liquidity. The combination of high returns on capital and efficient working capital management points to strong operational effectiveness.
| Metric | 2018–2020 (Avg) | 2021–2023 (Avg) | Last Year |
|---|---|---|---|
| ROCE % | 17.3% | 26.0% | 25.0% |
| Return on Equity % | 19.0% (5Y Avg) | 20.0% (3Y Avg) | 19.0% |
Financial Health & Prudence
The company's financial health is robust and managed with prudence. Leverage is very low, with a Debt-to-Equity ratio of just 0.13 as of March 2024. Although borrowings saw a temporary spike in FY2023, they have been significantly reduced in the latest fiscal year, demonstrating disciplined capital management. The company's ability to service its debt is outstanding, as evidenced by an Interest Coverage Ratio of 20.4x in FY2024, calculated from an operating profit of ₹897 Cr and interest expense of ₹44 Cr. This indicates a very low risk of default on its interest obligations. Additionally, the company has a consistent track record of sharing profits with shareholders, maintaining a healthy Dividend Payout ratio of around 34% in recent years.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Borrowings (₹ Cr) | 55 | 572 | 378 |
| Debt / Equity Ratio | 0.03 | 0.23 | 0.13 |
Shareholding & Ownership Structure
The ownership structure reflects strong alignment and investor confidence. Promoter holding is high and stable, at 53.78% as of March 2024. A majority stake held by promoters indicates long-term commitment. More notably, there is a clear trend of increasing institutional interest. Foreign Institutional Investors (FIIs) have steadily increased their stake from 7.54% in March 2021 to 11.06% in March 2024, signaling growing confidence from global investors. Domestic Institutional Investors (DIIs) also maintain a significant and stable holding of 18.38%. This strong and improving institutional presence, combined with high promoter ownership, provides a solid foundation of investor confidence and stability.
| Shareholding (%) | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Promoters | 54.00% | 53.93% | 53.78% |
| FIIs | 9.22% | 8.62% | 11.06% |
| DIIs | 16.89% | 19.08% | 18.38% |
The overall risk profile is low. The primary indicator of accounting quality is very positive, with Cash Flow from Operations significantly exceeding Net Profit in the latest two fiscal years. This suggests high-quality earnings and a low risk of aggressive accounting practices. Financial risks are well-contained; leverage is minimal, and the company's capacity to cover interest payments is exceptionally high, mitigating risks associated with its debt. The core financial and accounting metrics do not present any red flags. The primary risk observed is operational, related to the recent slowdown in quarterly growth, but this does not currently undermine the strong overall financial stability of the company.
Accounting quality red flags
The company exhibits strong signs of high accounting quality. A key indicator is the relationship between cash flow and reported profit. For the fiscal year ending March 2024, Cash from Operating Activity (CFO) was ₹801 Cr, substantially higher than the Net Profit of ₹553 Cr. A CFO/Net Profit ratio greater than 1 is a strong positive signal, indicating that profits are being converted into cash effectively. While this ratio was below 1 in FY2022, the strong performance in the two most recent years provides a high degree of confidence in the reported financial statements.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Net Profit (₹ Cr) | 386 | 410 | 553 |
| Cash from Operations (₹ Cr) | 170 | 626 | 801 |
| CFO / Net Profit Ratio | 0.44x | 1.53x | 1.45x |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102195.28Bearish
- SMA 202193.94Bearish
- SMA 502217.83Bearish
- EMA 102195.31Bearish
- EMA 202197.17Bearish
- EMA 502202.78Bearish
- DEMA 102195.23Bearish
- DEMA 202191.21Bullish
- DEMA 502202.39Bearish
- TEMA 102196.53Bearish
- TEMA 202193.08Bearish
- TEMA 502191.41Bullish
- MACD-3.70Bullish
- ADX12.85Weak Trend
- IndicatorValueSignal
- RSI45.85Neutral
- CCI-36.40Neutral
- ROC 90.32Bullish
- ROC 14-0.20Bearish
- ROC 25-0.10Bearish
- Stoch K51.68Neutral
- Stoch D56.50Neutral
- IndicatorValueSignal
- BB Upper2202.90Neutral
- BB Middle2193.94Neutral
- BB Lower2184.97Neutral
- ATR14.95High Volatility
- IndicatorValueSignal
- MFI34.83Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102195.70Bearish
- SMA 202199.54Bearish
- SMA 502200.94Bearish
- EMA 102197.26Bearish
- EMA 202201.71Bearish
- EMA 502198.52Bearish
- DEMA 102193.31Bearish
- DEMA 202196.25Bearish
- DEMA 502213.70Bearish
- TEMA 102195.66Bearish
- TEMA 202188.41Bullish
- TEMA 502205.54Bearish
- MACD-4.48Bearish
- ADX15.33Weak Trend
- IndicatorValueSignal
- RSI46.09Neutral
- CCI-57.18Neutral
- ROC 90.07Bullish
- ROC 140.06Bullish
- ROC 25-2.65Bearish
- Stoch K50.10Neutral
- Stoch D45.02Neutral
- IndicatorValueSignal
- BB Upper2222.27Neutral
- BB Middle2199.54Neutral
- BB Lower2176.80Neutral
- ATR21.47Low Volatility
- IndicatorValueSignal
- MFI35.31Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102199.98Bearish
- SMA 202213.32Bearish
- SMA 502183.71Bullish
- EMA 102202.22Bearish
- EMA 202201.29Bearish
- EMA 502179.37Bullish
- DEMA 102197.72Bearish
- DEMA 202210.14Bearish
- DEMA 502222.17Bearish
- TEMA 102191.00Bullish
- TEMA 202202.28Bearish
- TEMA 50N/AN/A
- MACD5.05Bearish
- ADX23.92Weak Trend
- IndicatorValueSignal
- RSI48.85Neutral
- CCI-62.07Neutral
- ROC 9-1.16Bearish
- ROC 14-0.10Bearish
- ROC 252.72Bullish
- Stoch K19.42Oversold
- Stoch D18.96Oversold
- IndicatorValueSignal
- BB Upper2268.45Neutral
- BB Middle2213.32Neutral
- BB Lower2158.18Neutral
- ATR34.26Low Volatility
- IndicatorValueSignal
- MFI48.79Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102206.89Bearish
- SMA 202188.70Bullish
- SMA 502111.40Bullish
- SMA 1002053.14Bullish
- SMA 2001904.99Bullish
- EMA 102200.56Bearish
- EMA 202184.21Bullish
- EMA 502132.00Bullish
- EMA 1002057.98Bullish
- EMA 2001956.29Bullish
- DEMA 102212.37Bearish
- DEMA 202218.56Bearish
- DEMA 502211.65Bearish
- DEMA 1002189.27Bullish
- DEMA 2002108.02Bullish
- TEMA 102207.65Bearish
- TEMA 202216.15Bearish
- TEMA 502219.14Bearish
- TEMA 1002221.89Bearish
- TEMA 2002181.92Bullish
- MACD24.47Bearish
- ADX26.92Strong Trend
- IndicatorValueSignal
- RSI54.90Neutral
- CCI12.03Neutral
- ROC 141.43Bullish
- ROC 254.98Bullish
- Stoch K52.37Neutral
- Stoch D57.47Neutral
- IndicatorValueSignal
- BB Upper2259.04Neutral
- BB Middle2188.69Neutral
- BB Lower2118.35Neutral
- ATR56.24Low Volatility
- IndicatorValueSignal
- MFI61.53Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 202056.59Bullish
- SMA 501866.88Bullish
- EMA 202061.29Bullish
- EMA 501926.05Bullish
- DEMA 202186.09Bullish
- DEMA 502076.63Bullish
- TEMA 202216.25Bullish
- TEMA 502141.65Bullish
- MACD94.52Bullish
- ADX37.28Strong Trend
- IndicatorValueSignal
- RSI67.60Neutral
- CCI160.96Overbought
- ROC 149.98Bullish
- ROC 2525.03Bullish
- Stoch K76.69Neutral
- Stoch D77.62Neutral
- IndicatorValueSignal
- BB Upper2273.15Neutral
- BB Middle2056.58Neutral
- BB Lower1840.02Neutral
- ATR111.39High Volatility
- IndicatorValueSignal
- MFI73.81Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 62002.98Bullish
- SMA 121862.84Bullish
- SMA 241821.78Bullish
- EMA 62015.60Bullish
- EMA 121917.31Bullish
- EMA 241792.54Bullish
- DEMA 62129.18Bullish
- DEMA 122050.26Bullish
- DEMA 242027.16Bullish
- TEMA 62162.69Bullish
- TEMA 122099.34Bullish
- TEMA 242012.31Bullish
- MACD303.32Bullish
- ADX30.79Strong Trend
- IndicatorValueSignal
- RSI68.65Neutral
- CCI129.58Overbought
- ROC 2513.76Bullish
- ROC 50175.24Bullish
- Stoch K65.23Neutral
- Stoch D67.20Neutral
- IndicatorValueSignal
- BB Upper2131.59Overbought
- BB Middle1810.74Neutral
- BB Lower1489.88Neutral
- ATR202.71High Volatility
- IndicatorValueSignal
- MFI72.91Neutral